Bactiguard Holding AB (CHIX:BACTBS) Risk Assessment


CHIX:BACTBS Bactiguard Holding AB CHIX:BACTBS
56 GF Score
Price kr128.60
GF Value kr266.73
! 2 Warning Signs
View Full Analysis

What is Bactiguard Holding AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bactiguard Holding AB is: No Data: Cannot be evaluated.

Bactiguard Holding AB  (CHIX:BACTBs) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bactiguard Holding AB Risk Assessment Related Terms

CHIX:BACTBS vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Bactiguard Holding AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bactiguard Holding AB Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bactiguard Holding AB's Risk Assessment falls into.


CHIX:BACTBS
56GF Score
Bactiguard Holding AB CHIX:BACTBS
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?

Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued. The current stock price of kr128.60 is trading 51.8% below its estimated GF Value™ of kr266.73.

Key valuation signals for CHIX:BACTBS:

  • Risk Assessment:
  • GF Value™: kr266.73 vs. price of kr128.60 (51.8% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bactiguard Holding AB Business Description

Other Exchanges BACTI B:Sweden5JE:Germany
Address Vasagatan 11, Stockholm, SWE, 111 20
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
56GF Score

Get the complete analysis for CHIX:BACTBS

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr128.60
Price
kr266.73
GF Value